The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...